-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Suzhou, China, October 8, 2021/PRNewswire/ - CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focusing on research, development and commercialization of innovative tumor immunotherapies and precision therapeutic drugs, It was announced today that the preclinical research data of the potential global best-in-class drug CS5001 (ROR1 ADC) has been selected for the 2021 33rd International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics) blockbuster study Abstract (late-breaking abstract, LBA) and present the research results in poster form (Poster ID: LBA008)
Research Field: Various Solid Tumors and Hematological Tumors Date: October 7-10, 2021 Report Format: Late-breaking Abstract (LBA) Title: CS5001 is a novel target with ROR1, Antibody-conjugated drug (ADC) with tumor-specific activation of pyrrolobenzodiazepine (PBD) protoxin, which is expected to be used in the treatment of hematological tumors and malignant solid tumors.
CS5001 is an ADC composed of a human monoclonal antibody targeting receptor tyrosine kinase-like orphan receptor 1, ROR1
CS5001 binds to human ROR1, but not to ROR2
CS5001 showed significant anti-tumor activity in both Jeko-1 and MDA-MB-231 xenograft tumor models, and was dose-dependent
Dr.
At present, CS5001 has completed the preclinical research required for clinical application.
In October 2020, CStone Pharmaceuticals and LegoChem Biosciences, Inc.
The research was jointly completed by CStone Pharmaceuticals, LCB Company, and South Korea's ABL Bio Company
About CStone Pharmaceuticals
CStone Pharmaceuticals (Hong Kong Stock Exchange Code: 2616) is a biopharmaceutical company that focuses on the research, development and commercialization of innovative tumor immunotherapy and precision treatment drugs to meet the ardent medical needs of cancer patients in China and around the world
Forward-looking statement
The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article
Source: CStone Pharmaceuticals
